Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited. Previous genetic, proteomic, imaging, and electrophysiological studies have identified potential biomarkers and phenotype modifiers, improving the understanding of motor neuron degeneration mechanisms. However, these findings have not yet been translated into a clinically useful biomarker algorithm. This observational study aims to develop a biomarker panel to support the diagnosis, prognosis, and stratification of patients with ALS. Clinical and molecular biomarkers previously associated with ALS phenotypes will be analyzed simultaneously and integrated into a multivariable predictive model. Clinical data and biological samples will be collected and analyzed to identify combinations of biomarkers associated with ALS phenotypes.
Age greater than 18 years.
Male and female patients with ALS diagnosed according to the El Escorial diagnostic criteria.
Sporadic or familial ALS cases.
Spinal-onset or bulbar-onset ALS cases.
Refusal to participate.
Individuals deprived of liberty (Article L1121-6), including those subject to judicial or administrative decisions or involuntary hospitalization.
Adults under legal protection (guardianship, curatorship, or judicial protection measures) (Article L1121-8).
Individuals not affiliated with, or not beneficiaries of, a French social security scheme (Article L1121-8-1).
University Hospital, Montpellier
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute
Collaborator